AJCP / Meeting AbstrActs from 14% to 34%, the deviation from the group average of 23% ranged from -9% to +11%. Six pathologist ND/ UNS rates were higher than the group average, five were lower, and one pathologist's ND/UNS rate corresponded to the group average. The ND/UNS rates demonstrated individual differences by each pathologist; however, the distribution of the individual rates was relatively symmetric about the group average. Even the lowest ND/UNS rate was higher than what most studies have published by different groups. We conclude that pathologists may yield individual differences in applying criteria for nondiagnostic/unsatisfactory FNAs. Low cellularity of the incoming samples, however, is an area needing to be addressed (perhaps best by rapid on-site assessment) to decrease overall ND/UNS rates and improve patient care.
from 14% to 34%, the deviation from the group average of 23% ranged from -9% to +11%. Six pathologist ND/ UNS rates were higher than the group average, five were lower, and one pathologist's ND/UNS rate corresponded to the group average. The ND/UNS rates demonstrated individual differences by each pathologist; however, the distribution of the individual rates was relatively symmetric about the group average. Even the lowest ND/UNS rate was higher than what most studies have published by different groups. We conclude that pathologists may yield individual differences in applying criteria for nondiagnostic/unsatisfactory FNAs. Low cellularity of the incoming samples, however, is an area needing to be addressed (perhaps best by rapid on-site assessment) to decrease overall ND/UNS rates and improve patient care. The risk of transmission of hepatitis C virus (HCV) or human immunodeficiency virus (HIV)from a transfusion is approximately one in 2 million donations per disease per transfusion. One cause is false-negative (FN) test results where the assay limit of detection is higher than viral load. Sigma metrics provides a quality measure of an assay in terms of defects per million which can be translated into FN per million results. The Cobas AmpliScreen HCV test v2.0 is approved for donor screening, and the Architect HIV Ag/Ab Combo assay is approved to be used as an alternative in urgent situations where traditional tests are unavailable or their use is impractical. We assessed our Roche Cobas AmpliPrep/ Cobas TaqMan System with the HCV test v2.0 assay, and Abbott Architect i2000SR with the HIV Ag/Ab Combo assay using sigma metrics to determine our FN result rates to better assess possible causes of residual viral transmission despite nucleic acid testing. Controls were selected at 2.84 log-copies/mL and at 2.74 log-copies/mL for HCV and HIV, respectively. The coefficients of variation (CVs) were calculated by repeated measures of control materials (n = 100 for HCV; n = 37 for HIV) after log transformation. For both assays, a 0.3 log-copies/mL variability limit was chosen as the allowable total error (TEa), representing a clinically significant change in viral load. Sigma metrics were calculated using the following equation: sigma metric = TEa/%CV. The %CVs for HCV and HIV assays were 21.96% and 22.48%, and sigma metrics were 4.5 and 4.4, respectively. A sigma value of 4 to 5 corresponds to 32 defects per million in the long-term sigma scale. Our results showed a higher FN rate of these two methods than the US Food and Drug Administration's goal. We also demonstrated the value of measuring sigma metrics when evaluating commercial screening methods. Determination of sigma metrics for other blood donor screening assays (eg, hepatitis B virus) is warranted.
